# Short-Course Radiotherapy, Nal-IRI, Capecitabine, and Camrelizumab for Locally Advanced MSS Rectal Cancer

> **NCT07521605** · PHASE2 · NOT_YET_RECRUITING · sponsor: **Guangdong Provincial People's Hospital** · enrollment: 44 (estimated)

## Conditions studied

- Rectal Cancer Patients

## Interventions

- **RADIATION:** Short-Course Radiotherapy
- **DRUG:** Liposomal Irinotecan (nal-IRI)
- **DRUG:** Capecitabine
- **DRUG:** Camrelizumab

## Key facts

- **NCT ID:** NCT07521605
- **Lead sponsor:** Guangdong Provincial People's Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-05-20
- **Primary completion:** 2031-12-31
- **Final completion:** 2034-12-31
- **Target enrollment:** 44 (ESTIMATED)
- **Last updated:** 2026-04-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07521605

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07521605, "Short-Course Radiotherapy, Nal-IRI, Capecitabine, and Camrelizumab for Locally Advanced MSS Rectal Cancer". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT07521605. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*